search
Back to results

Excisional Vacuum-Assisted Breast Biopsy

Primary Purpose

Atypical Ductal Hyperplasia, Ductal Carcinoma in Situ

Status
Recruiting
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Vacuum-assisted excisional biopsy
Not excisional biopsy
Sponsored by
European Institute of Oncology
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Atypical Ductal Hyperplasia

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria: Patients with suspicious breast lesions (BIRADS >3) Patients with a lesion <= of 15mm. Capable and willing to comply the specific informed consent form Patients with ADH biopsy results or low intermediate-grade DCIS Patients who will undergo surgery Exclusion Criteria: - Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study

Sites / Locations

  • Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCSRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

no excisional biopsy

excisional biosy

Arm Description

Patients in this arm underwent to an initial sequence of sampling (less than 4 g of tissue sampled)

Patients in this arm will undergo a second sequence of biopsy samples (at least 4g sampled)

Outcomes

Primary Outcome Measures

Percentage of patients with complete removal of lesion
Comparison of the percentage of patients with a lack of pathology (also in situ) at the surgery between the two groups

Secondary Outcome Measures

Full Information

First Posted
June 27, 2023
Last Updated
July 19, 2023
Sponsor
European Institute of Oncology
Collaborators
Ministero della Salute, Italy
search

1. Study Identification

Unique Protocol Identification Number
NCT05932758
Brief Title
Excisional Vacuum-Assisted Breast Biopsy
Official Title
Excisional Vacuum-Assisted Breast Biopsy (VAE): Application to Avoid Surgery in Atypical Ductal Hyperplasia and Low/Intermediate Grade Ductal Carcinoma in Situ of the Breast
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 17, 2023 (Actual)
Primary Completion Date
April 30, 2025 (Anticipated)
Study Completion Date
July 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
European Institute of Oncology
Collaborators
Ministero della Salute, Italy

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The goal of this prospective cohort study is to evaluate the possibility of vacuum-assisted excisional biopsy (VAE) to completely remove the pathology in case of small lesions for Atypical Ductal Hyperplasia (ADH) and low-intermediate grade Ductal Carcinoma in Situ (DCIS).
Detailed Description
Surgery is the current standard of care of breast lesions like the Ductal Carcinoma In Situ (DCIS) and the Atypical Ductal Hyperplasia (ADH). However, the survival benefit of surgical resection in patients with such lesions appears to be low, especially for ADH and low-grade DCIS where comorbidity of surgery and prior depression have been reported as important factors related to worse quality of life in these women. Patients with suspicious breast lesions (BIRADS>3) who are candidates for vacuum assisted breast biopsy will be prospectively select and enroll if the radiological lesion diameter is less than 15 mm. The investigators will select those patients in whom after an initial sequence of sampling (12 cores), and will check the complete macroscopic removal of the lesion (with radiograms of the biopsied part of the breast). Those patients (complete macroscopic removal, with real-time verification during the procedure) will be randomized into two groups. A first group of patients will finish the biopsy procedure after the first collection sequence (12 cores, 3 grams of tissue taken and complete macroscopic removal). A second group of patients (randomized subdivision) will undergo a second sequence of biopsy samples (other 4 cores and 1 gram of tissue taken) in the same session: the material collected will be sent separately to the pathologist.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atypical Ductal Hyperplasia, Ductal Carcinoma in Situ

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
300 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
no excisional biopsy
Arm Type
Other
Arm Description
Patients in this arm underwent to an initial sequence of sampling (less than 4 g of tissue sampled)
Arm Title
excisional biosy
Arm Type
Experimental
Arm Description
Patients in this arm will undergo a second sequence of biopsy samples (at least 4g sampled)
Intervention Type
Procedure
Intervention Name(s)
Vacuum-assisted excisional biopsy
Intervention Description
at least 4g of tissue sampled (excisional biopsy)
Intervention Type
Procedure
Intervention Name(s)
Not excisional biopsy
Intervention Description
biopsy with less than 4 g of tissue sampled
Primary Outcome Measure Information:
Title
Percentage of patients with complete removal of lesion
Description
Comparison of the percentage of patients with a lack of pathology (also in situ) at the surgery between the two groups
Time Frame
6 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with suspicious breast lesions (BIRADS >3) Patients with a lesion <= of 15mm. Capable and willing to comply the specific informed consent form Patients with ADH biopsy results or low intermediate-grade DCIS Patients who will undergo surgery Exclusion Criteria: - Patients with psychiatric, addictive, or any disorder, which compromises ability to give informed consent for participation in this study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Luca Nicosia, MD
Phone
+390294372449
Email
luca.nicosia@ieo.it
First Name & Middle Initial & Last Name or Official Title & Degree
Claudia Sangalli, MSc
Email
claudia.sangalli@ieo.it
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Luca Nicosia, MD
Organizational Affiliation
European Institute of Oncology IRCCS
Official's Role
Principal Investigator
Facility Information:
Facility Name
Breast Imaging Division, Radiology Department, IEO European Institute of Oncology IRCCS
City
Milan
ZIP/Postal Code
20141
Country
Italy
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Luca Nicosia, MD

12. IPD Sharing Statement

Learn more about this trial

Excisional Vacuum-Assisted Breast Biopsy

We'll reach out to this number within 24 hrs